[1] [1] BARNEDA-ZAHONERO B, PARRAM. Histone deacetylases and cancer［J］. Molecular Oncology, 2012, 6(6): 579-589.

[2] [2] PARK S Y, KIM J S. A short guide to histone deacetylases includ- ing recent progress on class II enzymes［J］. Experimental and Molecular Medicine, 2020, 52(2): 204-212.

[3] [3] MATHIAS R A, GUISE A J, CRISTEA I M. Post-translational modifications regulate class IIa histone deacetylase (HDAC) func- tion in health and disease［J］. Molelular & Cellular Proteomics, 2015, 14(3): 456-470.

[4] [4] NARITA T, WEINERT B T, CHOUDHARY C. Functions and mechanisms of non-histone protein acetylation［J］. Nature Review Molecular Cell Biology, 2019, 20(3): 156-174.

[5] [5] BURGER M , CHORY J. Structural and chemical biology of deacetylases for carbohydrates, proteins, small molecules and his- tones［J］. Communications Biology, 2018, 1: 217.

[6] [6] MILAZZO G, MERCATELLI D, DI MUZIO G, et al. Histone deacetylases (HDACs): evolution, specificity, role in transcrip- tional complexes, and pharmacological actionability［J］. Genes (Basel), 2020, 11(5): 556.

[7] [7] GATLA H R, MUNIRAJ N, THEVKAR P, et al. Regulation of chemokines and cytokines by histone deacetylases and an update on histone decetylase inhibitors in human diseases［J］. Interna- tional Journal of Molecular Sciences, 2019, 20(5): 1110.

[8] [8] GUISE A J, CRISTEA I M. Approaches for studying the subcellu- lar localization, interactions, and regulation of histone deacetylase 5 (HDAC5)［J］. Methods Molecular Biology, 2016, 1436: 47-84.

[9] [9] GRECO T M, YU F, GUISE A J, et al. Nuclear import of his- tone deacetylase 5 by requisite nuclear localization signal phos- phorylation［J］. Molecular & Cellular Proteomics, 2011, 10(2): M110.004317.

[10] [10] VEGA R B, HARRISON B C, MEADOWS E, et al. Protein ki- nases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5［J］. Molecular and Cellular Biology, 2004, 24( 19): 8374-8385.

[11] [11] HA C H, WANG W, JHUN B S, et al. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expres- sion and angiogenesis［J］. Journal of Biology Chemistry, 2008, 283(21): 14590-14599.

[12] [12] LINSEMAN D A, BARTLEY C M, LE S S, et al. Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca(2+) //calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival［J］. Journal of Biology Chemistry, 2003, 278(42): 41472-41481.

[13] [13] MCKINSEY T A, ZHANG C L, OLSON E N. Identification of a signal-responsive nuclear export sequence in class II histone deacetylases［J］. Molecular and Cellular Biology, 2001, 21( 18): 6312-6321.

[14] [14] HAWORTH R S, STATHOPOULOU K, CANDASAMY AJ, et al. Neurohormonal regulation of cardiac histone deacetylase 5 nuclear localization by phosphorylation-dependent and phosphorylation- independent mechanisms［J］. Circulation Research , 2012 , 110( 12): 1585-1595.

[15] [15] DENG X B, EWTON D Z, MERCER S E, et al. Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation［J］. Journal of Biology Chemistry, 2005, 280(6): 4894-4905.

[16] [16] WEEKS K L, RANIERI A, KARAS A, et al. Beta-adrenergic stimulation induces histone deacetylase 5 (HDAC5) nuclear accu- mulation in cardiomyocytes by B55alpha-PP2A-mediated dephos- phorylation［J］. Journal of the American Heart Association, 2017, 6(4): e004861.

[17] [17] GUISE A J, GRECO T M, ZHANG I Y, et al. Aurora B-dependent regulation of class IIa histone deacetylases by mitotic nuclear lo- calization signal phosphorylation［J］. Molecular Cell Proteomics, 2012, 11( 11): 1220-1229.

[18] [18] SOMAIA E E, ANDREW R G, EMAD A R, et al. Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome［J］. Cancer Research, 2009, 69(9): 3802-3809.

[19] [19] REDDY D, KHADE B, PANDYA R, et al. A novel method for iso- lation of histones from serum and its implications in therapeutics and prognosis of solid tumours［J］. Clinical Epigenetics, 2017, 9: 30.

[20] [20] PARK S Y, JUN J A, JEONG K J, et al. Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer［J］. Oncology Re- ports, 2011, 25(6): 1677-1681.

[21] [21] MüLLER B M, JANA L, KASAJIMA A, et al. Differential ex- pression of histone deacetylases HDAC1, 2 and 3 in human breast cancer: overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression［J］. BMC Cancer, 2013, 13: 215.

[22] [22] YANG Shuyun, LI Haibo, ZHANG Jianbing. Clinicopathologi- cal significance of HDAC1 mRNA expression in invasive breast cancer［J］. Journal of Clinical and Experimental Pathology, 2011, 27(9): 929-932.

[23] [23] LIU Pengyong. HDAC1 and E-cadherin expression in breast can- cer［D］. Jiamusi: Jiamusi University, 2020.

[24] [24] PATANI N, JIANG W G, NEWBOLD R F, et al. Histone-modifier gene expression profiles are associated with pathological and clini- cal outcomes in human breast cancer［J］. Anticancer Research, 2011, 31( 12): 4115-4125.

[25] [25] PEIXOTO P, CASTRONOVO V, MATHEUS N, et al. HDAC5 is required for maintenance of pericentric heterochromatin, and con- trols cell-cycle progression and survival of human cancer cells［J］. Cell Death Differentiation, 2012, 19(7): 1239-1252.

[26] [26] LI A, LIU Z, LI M, et al. HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer［J］. Oncotarget, 2016, 7(25): 37966-37978.

[27] [27] BERAA, RUSS E, MANOHARAN M S, et al. Proteomic analysis of inflammatory biomarkers associated with breast cancer recur- rence［J］. Military Medicine, 2020, 185(Suppl 1): 669-675.

[28] [28] ZHANG Z, YAMASHITA H, TOYAMA T, et al. HDAC6 expres- sion is correlated with better survival in breast cancer［J］. Clinical Cancer Research, 2004, 10(20): 6962-6968.

[29] [29] SAJI S, KAWAKAMI M, HAYASHI S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer［J］. Onco- gene, 2005, 24(28): 4531-4539.

[30] [30] LOU Changjie, ZHANG Qingyuan, ZHAO Wenhui. Expression of HDAC6 in ER positive breast cancer and relationship with ef- ficacy of endocrine therapy［J］. Progress in Modern Biomedicine, 2008( 10): 1897-1899.

[31] [31] CAO C, VASILATOS S N, BHARGAVA R, et al. Functional in- teraction of histone deacetylase 5 (HDAC5) and lysine-specific demethylase 1 (LSD1) promotes breast cancer progression［J］. Oncogene, 2017, 36( 1): 133-145.

[32] [32] HAN X, GUI B, XIONG C, et al. Destabilizing LSD1 by Jade-2 promotes neurogenesis: an antibraking system in neural develop- ment［J］. Molecular Cell, 2014, 55(3): 482-494.

[33] [33] WANG Xiang. Study on the mechanism of HDAC5 regulating mRNA m～6A modification in breast cancer cells［D］. Yichang: China Three Gorges University, 2021.

[34] [34] HUANG Y H, TAN M J, GOSINK M, et al. Histone deacetylase 5 is not a p53 target gene, but its overexpression inhibits tumor cell growth and induces apoptosis［J］. Cancer Research, 2002, 62( 10): 2913-2922.

[35] [35] SEN N, KUMARI R, SINGH M I, et al. HDAC5, a key compo- nent in temporal regulation of p53-mediated transactivation in response to genotoxic stress［J］. Molecular Cell, 2013, 52(3): 406-420.

[36] [36] ZHOU Y K, XIN J, MA J, et al. HDAC5 loss impairs RB repres- sion of pro-oncogenic genes and confers CDK4/6 inhibitor resis- tance in cancer［J］. Cancer Research, 2021, 81(6): 1486-1499.

[37] [37] HSIEH T H, HSU C Y, TSAI C F, et al. HDAC inhibitors target HDAC5, upregulate microRNA-125a-5p, and induce apoptosis in breast cancer cells［J］. Molecular Therapy, 2015, 23(4): 656-666.

[38] [38] BIAN X H, LIANG Z X, FENG A, et al. HDAC inhibitor sup- presses proliferation and invasion of breast cancer cells through regulation of miR-200c targeting CRKL［J］. Biochemical Phar- macology, 2018, 147: 30-37.

[39] [39] SALMENA L, POLISENO L, TAY Y, et al. A ceRNA hypothesis: the rosetta stone of a hidden RNA language?［J］. Cell, 2011, 146(3): 353-358.

[40] [40] LIU Y Y, LI M D, YU H H, et al. lncRNA CYTOR promotes tamoxifen resistance in breast cancer cells via sponging miR-125a- 5p［J］. International Journal of Molecular Medicine, 2020, 45(2): 497-509.

[41] [41] WANG J, XIE S, YANG J, et al. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy［J］. Journal of Hematology & Oncology, 2019, 12( 1): 81.

[42] [42] LI Y H, JIANG B H, ZHU H B, et al. Inhibition of long non- coding RNA ROR reverses resistance to Tamoxifen by inducing autophagy in breast cancer［J］. Tumour Biology, 2017, 39(6)： 1010428317705790.

[43] [43] GAO H L, HAO G J, SUN Y, et al. Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process［J］. Onco Targets Therapy, 2018, 11: 8001-8012.

[44] [44] RICHON V M, SANDHOFF T W, RIFKIND R A, et al. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation［J］. Proceedings of the Na- tional Academy of Sciences of the United States ofAmerica, 2000, 97( 18): 10014-10019.

[45] [45] DU Mo, ZHAO Meimei, GAO Yanrong, et al. Research progress of histone deacetylase inhibitors［J］. Fine and Specialty Chemi- cals, 2022, 30( 1): 46-50.

[46] [46] YOSHIDA M, KIJIMA M, AKITA M, et al. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A［J］. Journal of Biology Chemistry, 1990, 265(28): 17174-17179.

[47] [47] HUANG W T, TSAI Y H, CHEN S H, et al. HDAC2 and HDAC5 up-regulations modulate survivin and miR-125a-5p expressions and promote hormone therapy resistance in estrogen receptor posi- tive breast cancer cells［J］. Frontiers in Pharmacology, 2017, 8: 902.

[48] [48] CAO C Y, WU H, VASILATOS S N, et al. HDAC5-LSD1 axis regulates antineoplastic effect of natural HDAC inhibitor sulfora- phane in human breast cancer cells［J］. International Journal of Cancer, 2018, 143(6): 1388-1401.

[49] [49] OLTRA S S, CEJALVO J M, TORMO E, et al. HDAC5 Inhibi- tors as a potential treatment in breast cancer affecting very young women［J］. Cancers (Basel), 2020, 12(2): 412.

[50] [50] XUE Y, LIAN W W, ZHI J Q, et al. HDAC5-mediated deacety- lation and nuclear localisation of SOX9 is critical for tamoxifen resistance in breast cancer［J］. British Journal of Cancer, 2019, 121( 12): 1039-1049.

[51] [51] LACHENMAYER A, TOFFANIN S, CABELLOS L, et al. Com- bination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib［J］. Journal of Hepatology, 2012, 56(6): 1343-1350.

[52] [52] EL-AWADY R, SALEH E, HAMOUDI R, et al. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents［J］. Bioorganic & Medicinal Chemistry, 2021, 42: 116251.

[53] [53] KINGSTON B, CUTTS R J, BYE H, et al. Genomic profile of advanced breast cancer in circulating tumour DNA［J］. Nature Communications, 2021, 12( 1): 2423.